Market News

EPS for USA Truck, Inc. (USAK) Expected At $0.05; Macrogenics (MGNX) Sentiment Is 1.58

Analysts expect USA Truck, Inc. (NASDAQ:USAK) to report $0.05 EPS on February, 6.They anticipate $0.52 EPS change or 110.64% from last quarter’s $-0.47 EPS. USAK’s profit would be $396,845 giving it 102.70 P/E if the $0.05 EPS is correct. After having $0.05 EPS previously, USA Truck, Inc.’s analysts see 0.00% EPS growth. The stock decreased 4.47% or $0.96 during the last trading session, reaching $20.54. About 98,917 shares traded or 28.86% up from the average. USA Truck, Inc. (NASDAQ:USAK) has declined 68.51% since January 14, 2017 and is downtrending. It has underperformed by 85.21% the S&P500.

MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company has market cap of $755.97 million. The companyÂ’s advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It currently has negative earnings. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate.

Dafna Capital Management Llc holds 1.77% of its portfolio in MacroGenics, Inc. for 154,200 shares. Bb Biotech Ag owns 2.40 million shares or 1.23% of their US portfolio. Moreover, First Light Asset Management Llc has 0.89% invested in the company for 151,670 shares. The New York-based Tiger Management L.L.C. has invested 0.8% in the stock. Hood River Capital Management Llc, a Oregon-based fund reported 588,799 shares.

The stock increased 5.55% or $1.08 during the last trading session, reaching $20.53. About 354,983 shares traded or 19.99% up from the average. MacroGenics, Inc. (MGNX) has declined 9.76% since January 14, 2017 and is downtrending. It has underperformed by 26.46% the S&P500.

Analysts await MacroGenics, Inc. (NASDAQ:MGNX) to report earnings on February, 27. They expect $2.58 earnings per share, up 358.00% or $3.58 from last year’s $-1 per share. MGNX’s profit will be $95.00M for 1.99 P/E if the $2.58 EPS becomes a reality. After $-1.28 actual earnings per share reported by MacroGenics, Inc. for the previous quarter, Wall Street now forecasts -301.56% EPS growth.

Since January 1, 0001, it had 0 insider purchases, and 1 insider sale for $200,000 activity.

USA Truck, Inc., a truckload carrier, provides general commodities transportation services in the United States, Mexico, and Canada. The company has market cap of $163.02 million. It operates through two divisions, Trucking and USAT Logistics. It currently has negative earnings. The Trucking segment offers truckload services as a medium- to long-haul common carrier; and dedicated freight services.

Among 4 analysts covering USA Truck (NASDAQ:USAK), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. USA Truck had 14 analyst reports since August 19, 2015 according to SRatingsIntel. The stock of USA Truck, Inc. (NASDAQ:USAK) earned “Buy” rating by Cowen & Co on Friday, August 4. On Friday, September 29 the stock rating was upgraded by Stifel Nicolaus to “Buy”. Stephens maintained the stock with “Hold” rating in Monday, January 8 report. On Wednesday, August 2 the stock rating was maintained by Stifel Nicolaus with “Hold”. The firm has “Hold” rating given on Wednesday, August 19 by Zacks. The stock of USA Truck, Inc. (NASDAQ:USAK) earned “Buy” rating by Cowen & Co on Thursday, September 7. The firm has “Outperform” rating by Cowen & Co given on Thursday, November 5. Stifel Nicolaus upgraded the shares of USAK in report on Monday, November 7 to “Hold” rating. The rating was maintained by Cowen & Co on Monday, July 10 with “Buy”. The company was upgraded on Wednesday, February 8 by Avondale.

Investors sentiment increased to 1.25 in Q3 2017. Its up 0.48, from 0.77 in 2017Q2. It increased, as 6 investors sold USA Truck, Inc. shares while 14 reduced holdings. 11 funds opened positions while 14 raised stakes. 4.83 million shares or 22.76% more from 3.93 million shares in 2017Q2 were reported. Horrell invested in 0.22% or 28,070 shares. Morgan Stanley has 39,723 shares for 0% of their portfolio. Dimensional Fund Advsrs Limited Partnership, Texas-based fund reported 671,342 shares. Macquarie Group Limited holds 18,425 shares or 0% of its portfolio. Moreover, Callahan Advsr Limited Liability Company has 0.04% invested in USA Truck, Inc. (NASDAQ:USAK). Blackrock Inc owns 276,947 shares. The Massachusetts-based Portolan Capital Mgmt Limited Co has invested 1.19% in USA Truck, Inc. (NASDAQ:USAK). Tower Research Capital Ltd Liability (Trc) reported 1,003 shares. Scopus Asset Mgmt Lp stated it has 0.06% of its portfolio in USA Truck, Inc. (NASDAQ:USAK). Trexquant Inv Lp reported 13,394 shares. California Employees Retirement System owns 88,816 shares or 0% of their US portfolio. Bluecrest Cap Mngmt Limited has 0.01% invested in USA Truck, Inc. (NASDAQ:USAK). Jpmorgan Chase reported 23,812 shares or 0% of all its holdings. Spark Invest Management Limited Liability Co has invested 0.02% in USA Truck, Inc. (NASDAQ:USAK). Retail Bank Of Ny Mellon reported 30,296 shares stake.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *